Bullous Pemphigoid: A Focused Review on Antigen Epitopes

Area of Science:

• Immunodermatology
• Autoimmune Blistering Diseases

Background:

• Bullous pemphigoid (BP) is a prevalent autoimmune blistering disease.
• Autoantibodies against BP180 and BP230 are characteristic of BP.
• The NC16A domain of BP180 is a major target, but non-NC16A epitopes also play a role in disease heterogeneity.

Purpose of the Study:

• To review the immunological characteristics and clinical significance of BP180 and BP230 epitopes.
• To discuss the association of these epitopes with BP phenotypes, treatment responses, and prognosis.
• To evaluate current and emerging targeted therapies in the context of epitope-specific immunity.

Main Methods:

• Literature review of immunological characteristics and clinical significance of BP epitopes.
• Analysis of associations between epitopes, disease phenotypes, and treatment outcomes.
• Critical review of emerging targeted therapies and animal models.

Main Results:

• Non-NC16A epitopes contribute to the clinical heterogeneity of bullous pemphigoid.
• Validated animal models for non-NC16A epitopes are rare and have limited scope.
• Epitope profiling shows potential for disease stratification but is insufficient for routine therapeutic decisions.

Conclusions:

• Understanding epitope-specific immune responses is crucial for bullous pemphigoid pathogenesis and treatment.
• Further research is needed to clarify the role of non-NC16A epitopes and develop standardized detection methods.
• Future studies should focus on epitope-phenotype correlations and large cohorts to advance precision therapy for BP.